Sintx (SINT) 10-Q 14 Aug 18 2018 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2018	Aug. 10, 2018
Document And Entity Information
Entity Registrant Name	AMEDICA Corp
Entity Central Index Key	1,269,026
Document Type	10-Q
Document Period End Date	Jun. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		11,869,879
Trading Symbol	AMDA
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2,018

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 8,835	$ 539
Trade accounts receivable, net of allowance of $72 and $22, respectively	1,204	1,240
Prepaid expenses and other current assets	266	190
Inventories, net	1,237	1,241
Total current assets	11,542	3,210
Inventories, net	1,223	1,136
Property and equipment, net	1,212	1,446
Intangible assets, net	2,432	2,651
Goodwill	6,163	6,163
Other long-term assets	35	35
Total assets	22,607	14,641
Current liabilities:
Accounts payable	910	1,732
Accrued liabilities	967	2,682
Debt - related party	2,479	2,356
Debt		605
Derivative liabilities, current portion	6,061	896
Total current liabilities	10,417	8,271
Deferred rent	240	179
Other long-term liabilities	141	288
Derivative liabilities, net of current portion	500	461
Total liabilities	11,298	9,199
Commitments and contingencies
Stockholders' equity:
Convertible preferred stock, $0.01 par value, 130,000,000 shares authorized; 10,928 shares issued and outstanding.
Common stock, $0.01 par value, 250,000,000 shares authorized, 7,509,248 and 3,028,065 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively.	75	30
Additional paid-in capital	237,574	226,041
Accumulated deficit	(226,340)	(220,629)
Total stockholders' equity	11,309	5,442
Total liabilities and stockholders' equity	$ 22,607	$ 14,641

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Allowance of trade accounts receivable	$ 72	$ 22
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, shares authorized	130,000,000	130,000,000
Convertible preferred stock, shares issued	10,928	10,928
Convertible preferred stock, shares outstanding	10,928	10,928
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	7,509,248	3,028,065
Common stock, shares outstanding	7,509,248	3,028,065

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Income Statement [Abstract]
Product revenue	$ 2,039	$ 3,208	$ 4,330	$ 5,837
Costs of revenue	521	722	1,045	1,383
Gross profit	1,518	2,486	3,285	4,454
Operating expenses:
Research and development	1,311	1,342	2,550	2,358
General and administrative	1,116	1,084	2,590	2,196
Sales and marketing	1,124	1,784	2,322	3,426
Total operating expenses	3,551	4,210	7,462	7,980
Loss from operations	(2,033)	(1,724)	(4,177)	(3,526)
Other income (expenses):
Interest expense	(809)	(378)	(1,284)	(738)
Loss on extinguishment of derivative liabilities			(1,252)
Offering costs	(682)		(682)	(131)
Loss on extinguishment of debt			(340)
Change in fair value of derivative liabilities	1,209	403	2,020	2,182
Other income (loss), net	3	(4)	5	(2)
Total other income (expense) net	(279)	21	(1,533)	1,311
Net loss before income taxes	(2,312)	(1,703)	(5,710)	(2,215)
Provision for income taxes
Net loss	(2,312)	(1,703)	(5,710)	(2,215)
Deemed dividend related to the beneficial conversion feature and accretion of a discount on series B preferred stock	(7,334)		(7,334)
Net loss attributable to common stockholders	$ (9,646)	$ (1,703)	$ (13,044)	$ (2,215)
Net loss per share
Basic and diluted	$ (1.65)	$ (0.56)	$ (2.81)	$ (0.76)
Weighted average common shares outstanding:
Basic and diluted	5,847,984	3,022,073	4,636,346	2,918,240

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flow (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Cash flow from operating activities
Net loss	$ (5,710)	$ (2,215)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	290	293
Amortization of intangible assets	269	268
Amortization of lease incentive for tenant improvements	28	10
Non-cash interest expense	936	519
Loss on extinguishment of debt	340
Stock based compensation	34	119
Change in fair value of derivative liabilities	(2,020)	(2,182)
Gain on disposal of equipment	51	2
Loss on extinguishment of derivative liabilities	1,252
Provision for inventory reserve		400
Offering costs	682	131
Bad debt expense	35
Changes in operating assets and liabilities:
Trade accounts receivable	1	(354)
Prepaid expenses and other current assets	(76)	(115)
Inventories	(84)	170
Accounts payable and accrued liabilities	(1,280)	(475)
Net cash used in operating activities	(5,934)	(3,430)
Cash flows from investing activities
Purchase of property and equipment	(111)	(508)
Purchase of intangible asset	(50)
Proceeds from sale of property and equipment	4
Net cash used in investing activities	(157)	(508)
Cash flows from financing activities
Proceeds from issuance of warrant derivative liabilities, net of issuance costs ($682)	7,577	679
Proceeds from issuance of preferred stock, net of issuance costs ($668)	6,754
Proceeds from issuance of common stock in connection with the exercise of warrants, net of issuance costs	1,633
Proceeds from the issuance of debt	705
Proceeds from the issuance of common stock		3,128
Payments on debt	(2,282)	(3,324)
Net cash provided by financing activities	14,387	483
Net increase (decrease) in cash and cash equivalents	8,296	(3,455)
Cash and cash equivalents at beginning of period	539	6,915
Cash and cash equivalents at end of period	8,835	3,460
Noncash investing and financing activities
Debt exchange	$ 2,265
Payment of debt with common stock	1,453
Extinguishment of derivative liabilities through exercise of warrants	$ 565
Warrants issued in association with debt	98
Supplemental cash flow information
Cash paid for interest	$ 337	$ 219

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flow (Parenthetical) - USD ($) $ in Thousands	1 Months Ended	6 Months Ended
	Jan. 31, 2017	Jun. 30, 2018	Jun. 30, 2017
Issuance costs	$ 600,000
Common Stock [Member]
Issuance costs		$ 682	$ 682
Preferred Stock [Member]
Issuance costs		$ 668

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Organization and Summary of Significant Accounting Policies	1. Organization and Summary of Significant Accounting Policies Organization Amedica Corporation was incorporated in the state of Delaware on December 10, 1996. Amedica Corporation is a materials company focused on developing, manufacturing and selling silicon nitride ceramics that are used in medical implants and in a variety of industrial devices. At present, Amedica Corporation commercializes silicon nitride in the spine implant market and believes that its silicon nitride manufacturing expertise positions it favorably to introduce new and innovative products in the medical and non-medical fields. Amedica Corporation also believes that it is the first and only company to commercialize silicon nitride medical implants. Amedica Corporation acquired US Spine, Inc. (“US Spine”), a Delaware spinal products corporation with operations in Florida, on September 20, 2010. Amedica Corporation and US Spine are collectively referred to as “Amedica” or “the Company” in these condensed consolidated financial statements. The Company’s products are sold primarily in the United States. Basis of Presentation These unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) and include all assets and liabilities of the Company and its wholly-owned subsidiary, US Spine. All material intercompany transactions and balances have been eliminated in consolidation. SEC rules and regulations allow the omission of certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States, so long as the statements are not misleading. In the opinion of management, these financial statements and accompanying notes contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly the financial position and results of operations for the periods presented herein. These condensed consolidated financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, filed with the SEC on March 29, 2018. The results of operations for the six months ended June 30, 2018 are not necessarily indicative of the results to be expected for the year ending December 31, 2018. The Company’s significant accounting policies are set forth in Note 1 to the consolidated financial statements in its Annual Report on Form 10-K for the year ended December 31, 2017. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the periods then ended. Actual results could differ from those estimates. The most significant estimates relate to inventory, stock-based compensation, long-lived and intangible assets and the liability for preferred stock and common stock warrants. Liquidity and Capital Resources The condensed consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern within one year from the date of issuance of these condensed consolidated financial statements. For the six months ended June 30, 2018 and 2017, the Company incurred net losses of $5.7 million and $2.2 million, respectively, and used cash in operations of $5.9 million and $3.4 million, respectively. The Company had an accumulated deficit of $226.3 million and $220.6 million as of June 30, 2018 and December 31, 2017, respectively. To date, the Company’s operations have been principally financed by proceeds received from the issuance of preferred and common stock, convertible debt and bank debt and, to a lesser extent, cash generated from product sales. It is anticipated that the Company will continue to generate operating losses and use cash in operating activities. The Company’s continuation as a going concern is dependent upon its ability to increase sales, implement cost saving measures, maintain compliance with debt covenants and/or raise additional funds through the capital markets. Whether and when the Company can attain profitability and positive cash flows from operating activities or obtain additional financing is uncertain. In 2016, the Company implemented certain cost saving measures, including workforce and office space reductions, and will continue to evaluate additional cost savings alternatives during 2018. These additional cost savings measures may include additional workforce and research and development reductions, as well as cuts to certain other operating expenses. In addition to these cost-saving measures, the Company is taking measures to increase sales revenue. These efforts include actively generating additional scientific and clinical data to have it published in leading industry publications. The unique features of the Company’s silicon nitride material are not well known, and the Company believes that the publication of such data would help sales efforts as the Company approaches new prospects. The Company is also making additional changes to the sales strategy, including a focus on revenue growth of silicon nitride lateral lumbar implants, the recently developed pedicle screw system known as Taurus, a variation of the Taurus system known as Taurus MIS and a newly developed interbody device known as C+CSC with Lumen. The Company has common stock that is publicly traded and has been able to successfully raise capital when needed since the date of the Company’s initial public offering. The Company has engaged in discussions with investment and banking firms to examine financing alternatives, including options to encourage the exercise of outstanding warrants and other lending alternatives. To this effect, in March 2018, the Company closed on gross proceeds of $1.4 million, before payment of placement agent fees and costs on a warrant reprice and exercise transaction. See discussion regarding Warrant Reprice March 2018 in Note 8 below. Additionally, on May 14, 2018, we closed on a public offering of units, consisting of convertible preferred stock and warrants, for gross proceeds of $15.0 million, which excludes underwriting discounts and commissions and offering expenses payable by the Company. These uncertainties create substantial doubt about our ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties. Reverse Stock Split On November 10, 2017, the Company effected a 1 for 12 reverse stock split of the Company’s common stock. The par value and the authorized shares of the common and convertible preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these condensed consolidated financial statements have been adjusted retroactively to reflect the reverse stock split. Significant Accounting Policies There have been no significant changes to the Company’s significant accounting policies as described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017. New Accounting Pronouncements Not Yet Adopted In January 2017, the Financial Accounting Standards Board (“FASB”) issued ASU 2017-04 Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment In August 2016, the FASB updated accounting guidance on the following eight specific cash flow classification issues: (1) debt prepayment or debt extinguishment costs; (2) settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; (3) contingent consideration payments made after a business combination; (4) proceeds from the settlement of insurance claims; (5) proceeds from the settlement of corporate-owned life insurance policies, including bank-owned life insurance policies; (6) distributions received from equity method investees; (7) beneficial interests in securitization transactions; and (8) separately identifiable cash flows and application of the predominance principle. Under existing U.S. GAAP, there is no specific guidance on the eight cash flow classification issues aforementioned. These updates are effective for the Company for its annual period beginning January 1, 2019, and interim periods therein, with early adoption permitted. The guidance in this standard is not expected to have a material impact on the financial statements of the Company. In February 2016, the FASB updated the accounting guidance related to leases as part of a joint project with the International Accounting Standards Board (“IASB”) to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Under the new guidance, a lessee will be required to recognize assets and liabilities for capital and operating leases with lease terms of more than 12 months. Additionally, this update will require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases, including qualitative and quantitative requirements. The standard is effective for the Company for its annual period beginning January 1, 2020, and interim periods therein, with early adoption permitted. The Company is currently evaluating the potential impact this new standard may have on its financial statements but believes the most significant change will relate to building leases. In May 2014, in addition to several amendments issued during 2016, the FASB updated the accounting guidance related to revenue from contracts with customers, which supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle is that a company should recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The standard defines a five-step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP. The standard is effective for the Company for its annual period beginning January 1, 2019, and interim periods therein, and shall be applied either retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. The Company is in the preliminary stages of evaluating the impact that the new standard will have on its financial statements. The Company has reviewed all other recently issued, but not yet adopted, accounting standards, in order to determine their effects, if any, on its results of operations, financial position or cash flows. Based on that review, the Company believes that no other pronouncements will have a significant effect on its financial statements. New Accounting Pronouncements Adopted During the Six Months Ended June 30, 2018 In March 2016, the FASB updated the accounting guidance related to stock compensation. This update simplifies the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as the well as classification in the statement of cash flows. The standard is effective for the Company for its annual period beginning January 1, 2018. The guidance in this standard did not have a material impact on the financial statements of the Company. The Company early adopted ASU 2017-11 - Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception.

Basic and Diluted Net Loss Per

Basic and Diluted Net Loss Per Common Share	6 Months Ended
	Jun. 30, 2018
Earnings Per Share [Abstract]
Basic and Diluted Net Loss Per Common Share	2. Basic and Diluted Net Loss per Common Share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are primarily comprised of warrants for the purchase of common stock, Series B Convertible Preferred stock and stock options. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding because their effect would have been anti-dilutive due to the Company reporting a net loss. The Company had potentially dilutive securities, shares of common stock, totaling approximately 21.2 million and 1.5 million as of June 30, 2018 and 2017, respectively.

Inventories, Net

Inventories, Net	6 Months Ended
	Jun. 30, 2018
Inventory Disclosure [Abstract]
Inventories, Net	3. Inventories, net Inventories consisted of the following (in thousands): June 30, 2018 December 31, 2017 Raw materials $ 667 $ 740 WIP 75 52 Finished goods 1,718 1,585 $ 2,460 $ 2,377 Finished goods included consigned inventory totaling approximately $1.7 million and $0.5 million as of June 30, 2018 and December 31, 2017. As of June 30, 2018, inventories totaling $1.2 million and $1.2 million were classified as current and long-term, respectively. Inventories classified as current represent the carrying value of inventories as of June 30, 2018, that management estimates will be sold by June 30, 2019.

Intangible Assets

Intangible Assets	6 Months Ended
	Jun. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	4. Intangible Assets Intangible assets consisted of the following (in thousands): June 30, 2018 December 31, 2017 Developed technology $ 4,685 $ 4,685 Customer relationships 3,990 3,990 Other patents and patent applications 562 562 Trademarks 400 350 9,637 9,587 Less: accumulated amortization (7,205 ) (6,936 ) $ 2,432 $ 2,651 Amortization expense is expected to approximate $260,000 for the remainder of 2018, $536,000 per year through 2021, $369,000 in 2022 and total $140,000 thereafter, until fully amortized.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurements	5. Fair Value Measurements Financial Instruments Measured and Recorded at Fair Value on a Recurring Basis The Company has issued certain warrants to purchase shares of common stock, which are considered derivative liabilities because they have registration rights which could require a cash settlement and are re-measured to fair value at each reporting period in accordance with accounting guidance. Fair value is based on the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, under a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows: Level 1 - quoted market prices for identical assets or liabilities in active markets. Level 2 - observable prices that are based on inputs not quoted on active markets but corroborated by market data. Level 3 - unobservable inputs reflecting management’s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment. The Company classifies assets and liabilities measured at fair value in their entirety based on the lowest level of input that is significant to their fair value measurement. No financial assets were measured on a recurring basis as of June 30, 2018 and December 31, 2017. The following tables set forth the financial liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of June 30, 2018 and December 31, 2017: Fair Value Measurements as of June 30, 2018 Description Level 1 Level 2 Level 3 Total Derivative liability Common stock warrants $ - $ - $ 6,561 $ 6,561 Fair Value Measurements as of December 31, 2017 Description Level 1 Level 2 Level 3 Total Derivative liability Common stock warrants $ - $ - $ 1,357 $ 1,357 The Company did not have any transfers of assets and liabilities between Level 1 and Level 2 of the fair value measurement hierarchy during the six months ended June 30, 2018 and 2017. Common Stock Warrants Balance as of December 31, 2016 $ (3,665 ) Issuances of warrants classified as derivatives (810 ) Change in fair value 2,182 Balance as of June 30, 2017 $ (2,293 ) Balance as of December 31, 2017 $ (1,357 ) Issuances of warrants classified as derivatives (7,577 ) Change in fair value 2,020 Exercise of warrants 565 Other, net (212 ) Balance as of June 30, 2018 $ (6,561 ) Common Stock Warrants The Company has issued certain warrants to purchase shares of common stock, which are considered derivative liabilities because they have registration rights which could require a cash settlement and are re-measured to fair value at each reporting period in accordance with accounting guidance. As of June 30, 2018 and December 31, 2017, $0.5 million and $0.5 million, respectively, of the derivative liability was calculated using the Black-Scholes-Merton valuation model. As of June 30, 2018 and December 31, 2017, $6.1 million and $0.9 million of the derivative liability was calculated using the Monte Carlo Simulation valuation model. The assumptions used in estimating the common stock warrant liability using the Black-Scholes-Merton valuation model as of June 30, 2018 and December 31, 2017 were as follows: June 30, 2018 December 31, 2017 Weighted-average risk-free interest rate 2.73 % 1.89 % Weighted-average expected life (in years) 4.8 1.9 Expected dividend yield - % - % Weighted-average expected volatility 66 % 107 % The assumptions used in estimating the common stock warrant liability using the Monte Carlo Simulation valuation model as of June 30, 2018 and December 31, 2017 were as follows: June 30, 2018 December 31, 2017 Weighted-average risk-free interest rate 2.73 % 2.2 % Weighted-average expected life (in years) 3.7 3.6 Expected dividend yield - % - % Weighted average expected volatility 68 % 64 % In addition, if at any time after the second anniversary of the issuance of the warrant, both: (1) the 30-day volume weighted average price of the Company’s stock exceeds $3.00; and (2) the average daily trading volume for such 30-day period exceeds $350,000, the Company may call this warrant for $0.01 per share. Because of the call provisions, management believes the Monte Carlo Simulation valuation model provides a better estimate of fair value for the warrants issued during July 2016 and January 2017 than the Black-Scholes-Merton valuation model.

Accrued Liabilities

Accrued Liabilities	6 Months Ended
	Jun. 30, 2018
Payables and Accruals [Abstract]
Accrued Liabilities	6. Accrued Liabilities Accrued liabilities consisted of the following (in thousands): June 30, 2018 December 31, 2017 Payroll and related expense $ 589 $ 311 Commissions 233 477 Royalties 76 96 Interest payable - 6 Final loan payment fees - 1,650 Other 69 142 $ 967 $ 2,682

Debt

Debt	6 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
Debt	7. Debt L2 Capital Debt On January 31, 2018, the Company signed a promissory note in the aggregate principal amount of up to $0.84 million (the “L2 Note”) for an aggregate purchase price of up to $0.75 million and warrants to purchase up to an aggregate of 68,257 shares of common stock of the Company (the “Warrants”) at an exercise price of $3.31 per share. The maturity date is six months from date of funding. The L2 Note bears interest at a rate of 8% per year and a default interest rate of 18% per year. The L2 Note may be converted by the holder of the L2 Note at any time following an event of default. The conversion price of the L2 Note in the event of a default is equal to the product of (i) 0.70 multiplied by (ii) the lowest volume weighted average price, or VWAP, of the Company’s common stock during the 20-day trading period ending in the holder of the L2 note’s sole discretion on the last complete trading day prior to conversion, or, the conversion date. On May 14, 2018, the Company closed on an underwritten public offering of units, consisting of convertible preferred stock and warrants, for gross proceeds of $15.0 million. Part of the proceeds from this offering were used to pay off the outstanding debt with L2 Capital. The total payoff amount totaled $1.1 million, with a net of $0.7 in principal and $0.4 in interest. Hercules and MEF I, LP/Anson Investments Debt Exchange On January 3, 2018, the Company entered into an Assignment Agreement (the “Assignment Agreement”) with MEF I, LP and Anson Investments Master Fund (collectively the “Assignees” and each an “Assignee”), Hercules Technology III, L.P. (“HT III”) and Hercules Capital, Inc. (“HC” and, together with HT III, “Hercules”), pursuant to which Hercules assigned to the Assignees all amounts remaining due under the Loan and Security Agreement, dated June 30, 2014, as amended, between the Company and Hercules (the “Loan and Security Agreement”) and (2) the note (the “Hercules Note”) between the Company and Hercules evidencing the amounts due under the Loan and Security Agreement. The total amount assigned by Hercules to the Assignees in the aggregate was $2,264,623 and is secured by the same collateral underlying the Loan and Security Agreement. Subsequently, the Company entered into an exchange agreement pursuant to which the Assignees agreed to exchange the Hercules Term Loan obligation acquired by them for two senior secured convertible promissory notes issued by the Company, each in the principal amount of $1.1 million for an aggregate principal amount of $2.2 million, (the “Exchange Notes”). The Exchange Notes will mature on February 3, 2019 (the “Maturity Date”). The Exchange Notes bear interest at a rate of 15% per annum. Prior to the Maturity Date, principal and interest accrued under the Exchange Notes is payable in cash or, if certain conditions are met, payable in shares of common stock of the Company. All principal accrued under the Exchange Notes are convertible into shares of the Company’s common stock (“Conversion Shares”) at the election of the holders at any time at a fixed conversion price of $3.87 per share. Upon the occurrence of an event of default, the Assignees are entitled to convert all or any part of their Exchange Notes at a conversion price (the “Alternate Conversion Price”) equal to 70% of the lowest traded price of the Company’s common stock during the ten trading days prior to the conversion date, provided that (i) in no event may the Alternate Conversion Price be less than $1.75 per share and (ii) the Assignees shall not be entitled to receive more than 19.99% of the outstanding common stock. So long as these Exchange Notes remain outstanding or the Assignees hold any Conversion Shares, the Company is prohibited from entering into any financing transaction pursuant to which the Company sells its securities at a price lower than $1.75 per share. The Exchange Notes are secured by a first priority security interest in substantially all assets, including intellectual property, of the Company and contains covenants restricting payments to certain Company affiliates. On May 14, 2018, the Company closed on an underwritten public offering of units, consisting of convertible preferred stock and warrants, for gross proceeds of $15.0 million. Part of the proceeds from this offering were used to pay off the outstanding debt with MEF I, L.P. and Anson Investments. The total payoff was $1.6 million, with $1.4 million in principal and $0.2 million in interest. North Stadium Term Loan – Related Party (Extension) In July 2018, the Company entered into an extension to the term loan with North Stadium Investments, LLC. The extension moved the due date of the loan from July 28, 2018 to October 28, 2018, at which time all principal and unpaid interest are due and payable. The monthly interest only payments will continue through the payoff on October 28, 2018. North Stadium Term Loan – Related Party On July 28, 2017, the Company entered into a $2.5 million term loan (the “North Stadium Loan”) with North Stadium Investments, LLC (“North Stadium”), a company owned and controlled by the Company’s Chief Executive Officer and Chairman of the Board. The North Stadium Loan bears interest at 10% per annum and requires the Company to make monthly interest only payments from September 5, 2017 through July 5, 2018. All principal and unpaid interest (if any) under the Loan are due and payable on July 28, 2018. The North Stadium Loan is secured by substantially all of the Company’s assets but is junior to the security interest in assets encumbered by the Hercules Term Loan now held by MEF I and Anson Investments. In connection with the North Stadium Loan, the Company also issued North Stadium a warrant to purchase up to 55,000 shares of the Company’s common stock at a purchase price of $5.04 per share, subject to a 5-year term. The relative estimated value of the warrants on the date of grant approximated $0.2 million, was recorded as a debt discount and is being amortized as interest expense over the life of the term loan. Hercules Term Loan On June 30, 2014, the Company entered into a Loan and Security Agreement with Hercules which provided the Company with a $20.0 million term loan. The Hercules Term Loan matured on January 1, 2018. The Hercules Term Loan included a $0.2 million closing fee, which was paid to Hercules on the closing date of the loan. The closing fee was recorded as a debt discount and was amortized to interest expense over the life of the loan. The Hercules Term Loan also included a non-refundable final payment fee of $1.7 million. The final payment fee was accrued and recorded to interest expense over the life of the loan. On January 3, 2018, the Hercules Term Loan and all amounts owing thereunder were assigned to MEF I and Anson Investments. See discussion above for a more detailed description of that transaction. See discussion below with respect to the assignment of $3.0 million of the principal balance of the Hercules Term Loan to Riverside Merchant Partners, LLC (“Riverside”) and the subsequent agreement between the Company and Riverside to exchange the $3.0 million of the Hercules Term Loan held by Riverside for subordinated convertible promissory notes in the aggregate principal amount of $3.0 million. Hercules and Riverside Debt Exchange On April 4, 2016, the Company entered into an Assignment and Second Amendment to Loan and Security Agreement (the “Assignment Agreement”) with Riverside and Hercules, pursuant to which Hercules sold $1.0 million of the principal amount outstanding under the Hercules Term Loan to Riverside. In addition, pursuant to the terms of the Assignment Agreement, Riverside acquired an option to purchase an additional $2.0 million of the principal amount outstanding under the Hercules Term Loan from Hercules. Riverside subsequently exercised its option in full and acquired the additional $2.0 million of the outstanding principal amount of the Hercules Term Loan. Long-term debt consisted of the following (in thousands): June 30, 2018 December 31, 2017 Outstanding Principal Unamortized Discount and Debt Issuance Costs Net Carrying Amount Outstanding Principal Unamortized Discount and Debt Issuance Costs Net Carrying Amount Hercules Term Loan $ - $ - $ - $ 605 $ - $ 605 North Stadium Loan 2,500 (21 ) 2,479 2,500 (144 ) 2,356 Total debt 2,500 (21 ) 2,479 3,105 (144 ) 2,961 Less: Current portion (2,500 ) 21 (2,479 ) (3,105 ) 144 (2,961 ) Long-term debt $ - $ - $ - $ - $ - $ -

Equity

Equity	6 Months Ended
	Jun. 30, 2018
Equity [Abstract]
Equity	8. Equity May-June 2018 Preferred Stock Conversion During both May 2018 and June 2018, Series B Convertible Preferred shareholders of the Company converted 4,072 shares of Series B Convertible Preferred Stock into 3,086,570 shares of common stock. May 2018 Warrant Exercise During March 2018, the Company repriced 832,000 warrants dated July 8, 2016. During May 2018, an additional 145,834 of the repriced warrants were exercised resulting in gross proceeds of $0.3 million. May 2018 Unit Offering On May 14, 2018, the Company closed on an underwritten public offering of units (“the Units”), consisting of convertible preferred stock and warrants, for gross proceeds of $15.0 million, which excludes underwriting discounts and commissions and offering expenses payable by Amedica. The offering was priced at a public offering price of $1,000 per unit. Each unit consisted of one share of Series B Convertible Preferred Stock, with a stated value of $1,100, and warrants to purchase up to 758 shares of common stock (the “May 2018 Warrants”). The May 2018 Warrants are initially exercisable at an exercise price of $1.60 per share and expire 5 years from the date of issuance. The Series B Preferred Stock is convertible into shares of common stock by dividing the stated value of $1,100 by: (i) for the first 40 trading days following the closing of this offering, $1.4512 (the “Conversion Price”), (ii) after 40 trading days but prior to the 81st trading day, the lesser of  (a) the Conversion Price and (b) 87.5% of the lowest volume weighted average price for our Common Stock as reported at the close of trading on the market reporting trade prices for the Common Stock during the five trading days prior to the 41st trading day, and (iii) after 80 trading days, the lesser of  (a) the Conversion Price and (b) 87.5% of the lowest volume weighted average price for our Common Stock as reported at the close of trading on the market reporting trade prices for the Common Stock during the five trading days prior to the date of the notice of conversion. In the case of (ii)(b) and (iii)(b) above, the share price shall not be less than $0.48 (the “Floor Price”). Each of the Conversion Price and Floor Price is subject to adjustment in certain circumstances. The Company raised $15.0 million associated with the issuance of the Units, with $6.8 million, net of issuance costs of $0.6 million, allocated to the preferred stock and $6.9 million, net of issuance costs of $0.7 million, allocated to the warrants. In association with the warrants that were recorded as a derivative liability, the Company immediately expensed approximately $0.7 million of issuance costs. The 15,000 preferred shares were initially convertible into 11,369,900 shares of common stock and had an effective conversion rate of $1.45 per share based on the proceeds that were allocated to them. The conversion price was adjusted to $0.6543, effective July 12, 2018. Warrant Reprice March 2018 During the three months ended March 31, 2018, the Company entered into a warrant amendment agreement (the “Amendment Agreement”) with certain holders of previously issued Series E Common Stock Purchase Warrants (collectively, “Investors”). In connection with that certain Series E Common Stock Purchase Warrant between the Company and Investors dated July 8, 2016, the Company issued to Investors warrants to purchase up to 832,000 shares of common stock (the “Warrant Shares”) at an exercise price of $12.00 per share, (the “Investors Warrants”). Under the terms of the Amendment Agreement, in consideration of Investors exercising 668,335 of the Investors Warrants (the “Warrant Exercise”), the exercise price per share of the Investor Warrants was reduced to $2.125 per share. 668,335 of the Investors Warrants were exercised resulting in gross proceeds to the Company of $1.4 million before payment of placement agent fees and costs. In addition, and as further consideration, the Company issued to Investors new warrants to purchase up to the number of shares of common stock equal to 100% of the number of Warrant Shares issued pursuant to the Warrant Exercise at an exercise price per share equal to $2.00 per share. January 2017 Offering During 2017, the Company completed a secondary offering in which the Company sold 741,667 shares of common stock and warrants to purchase 363,750 shares of common stock. The Company received approximately $3.9 million in proceeds from the offering, with $3.1 million, net of issuance costs of $0.6 million, allocated to common stock and $0.8 million allocated to the warrants. In association with the warrants that were recorded as a derivative liability, the Company immediately expensed $0.1 million of issuance costs. The warrants became exercisable on the closing date, expire on the five-year anniversary of the closing date, and have an initial exercise price per share equal to $6.60 subject to adjustments for events of recapitalization, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting the Company’s common stock. July 2016 Offering In July 2016, the Company completed a secondary offering in which the Company sold 5,258,000 Class A Units, including 1,650,000 units sold pursuant to the exercise by the underwriters of their over-allotment option, priced at $1.00 per unit, and 7,392 Class B Units, priced at $1,000 per unit. Each Class A Unit consisted of 1/12th share of common stock and one warrant to purchase 1/12th share of common stock. Each Class B Unit consisted of one share of preferred stock convertible into 83 shares of common stock and warrants to purchase 83 shares of common stock. The securities comprising the units were immediately separable and were issued separately. In total, the Company issued 438,167 shares of common stock, 7,392 shares of preferred stock convertible into 616,000 shares of common stock and warrants to purchase 1,054,167 shares of common stock at a fixed exercise price of $12.00 per share. The Company received proceeds of approximately $11.4 million, net of underwriting and other offering costs. The Company raised $4.9 million associated with the Class A Units, with $2.5 million, net of issuance costs of $0.3 million, allocated to the common stock and $2.4 million allocated to the warrants. The Company also raised $7.0 million associated with the Class B Units with $3.6 million, net of issuance costs of $0.4 million, allocated to preferred stock and $3.4 million allocated to the warrants. The $5.8 million allocated to warrants were recorded as a derivative liability. In association with the warrants that were recorded as a derivative liability, the Company immediately expensed approximately $0.5 million of issuance costs. The 7,392 preferred shares were convertible into 616,000 shares of common stock and had an effective conversion rate of $6.48 per share based on the proceeds that were allocated to them. Subsequent to the secondary offering, all 7,392 shares of convertible preferred stock have been converted into 616,000 shares of common stock. Furthermore, the Company received $0.4 million and issued 37,208 shares of common stock upon the exercise of certain warrants issued in the secondary offering.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	9. Stock-Based Compensation A summary of the Company’s outstanding stock option activity for the six months ended June 30, 2018 is as follows: Options Weighted- Exercise Price Weighted- Average Intrinsic Value As of December 31, 2017 11,302 $ 264.26 7.3 $ - Granted - - - - Exercised - - - - Forfeited - - - - Expired - - - - As of June 30, 2018 11,302 $ 264.26 6.8 $ - Exercisable as of June 30, 2018 10,161 $ 272.59 7.7 $ - Expected to vest as of June 30, 2018 11,302 $ 264.26 6.8 $ - The Company estimates the fair value of each stock option on the grant date using the Black-Scholes-Merton valuation model, which requires several estimates including an estimate of the fair value of the underlying common stock on grant date. The expected volatility was based on an average of the historical volatility of a peer group of similar companies. The expected term was calculated utilizing the simplified method. The risk-free interest rate was based on the U.S. Treasury yield curve in effect at the time of grant for the expected term of the option. Summary of Stock-Based Compensation Expense Total stock-based compensation expense included in the condensed consolidated statements of operations is allocated as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Cost of revenue $ - $ 5 $ - $ 10 Research and development - 24 - 50 General and administrative 6 23 19 46 Selling and marketing 4 7 15 13 Capitalized into inventory - - - - $ 10 $ 59 $ 34 $ 119 Unrecognized stock-based compensation as of June 30, 2018 is as follows (in thousands): Unrecognized Stock-Based Compensation Weighted (in years) Stock options $ 3 -

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. Commitments and Contingencies From time to time, the Company is subject to various claims and legal proceedings covering matters that arise in the ordinary course of its business activities. Management believes any liability that may ultimately result from the resolution of these matters will not have a material adverse effect on the Company’s consolidated financial position, operating results or cash flows.

Organization and Summary of S17

Organization and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Organization	Organization Amedica Corporation was incorporated in the state of Delaware on December 10, 1996. Amedica Corporation is a materials company focused on developing, manufacturing and selling silicon nitride ceramics that are used in medical implants and in a variety of industrial devices. At present, Amedica Corporation commercializes silicon nitride in the spine implant market and believes that its silicon nitride manufacturing expertise positions it favorably to introduce new and innovative products in the medical and non-medical fields. Amedica Corporation also believes that it is the first and only company to commercialize silicon nitride medical implants. Amedica Corporation acquired US Spine, Inc. (“US Spine”), a Delaware spinal products corporation with operations in Florida, on September 20, 2010. Amedica Corporation and US Spine are collectively referred to as “Amedica” or “the Company” in these condensed consolidated financial statements. The Company’s products are sold primarily in the United States.
Basis of Presentation	Basis of Presentation These unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) and include all assets and liabilities of the Company and its wholly-owned subsidiary, US Spine. All material intercompany transactions and balances have been eliminated in consolidation. SEC rules and regulations allow the omission of certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States, so long as the statements are not misleading. In the opinion of management, these financial statements and accompanying notes contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly the financial position and results of operations for the periods presented herein. These condensed consolidated financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, filed with the SEC on March 29, 2018. The results of operations for the six months ended June 30, 2018 are not necessarily indicative of the results to be expected for the year ending December 31, 2018. The Company’s significant accounting policies are set forth in Note 1 to the consolidated financial statements in its Annual Report on Form 10-K for the year ended December 31, 2017.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the periods then ended. Actual results could differ from those estimates. The most significant estimates relate to inventory, stock-based compensation, long-lived and intangible assets and the liability for preferred stock and common stock warrants.
Liquidity and Capital Resources	Liquidity and Capital Resources The condensed consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern within one year from the date of issuance of these condensed consolidated financial statements. For the six months ended June 30, 2018 and 2017, the Company incurred net losses of $5.7 million and $2.2 million, respectively, and used cash in operations of $5.9 million and $3.4 million, respectively. The Company had an accumulated deficit of $226.3 million and $220.6 million as of June 30, 2018 and December 31, 2017, respectively. To date, the Company’s operations have been principally financed by proceeds received from the issuance of preferred and common stock, convertible debt and bank debt and, to a lesser extent, cash generated from product sales. It is anticipated that the Company will continue to generate operating losses and use cash in operating activities. The Company’s continuation as a going concern is dependent upon its ability to increase sales, implement cost saving measures, maintain compliance with debt covenants and/or raise additional funds through the capital markets. Whether and when the Company can attain profitability and positive cash flows from operating activities or obtain additional financing is uncertain. In 2016, the Company implemented certain cost saving measures, including workforce and office space reductions, and will continue to evaluate additional cost savings alternatives during 2018. These additional cost savings measures may include additional workforce and research and development reductions, as well as cuts to certain other operating expenses. In addition to these cost-saving measures, the Company is taking measures to increase sales revenue. These efforts include actively generating additional scientific and clinical data to have it published in leading industry publications. The unique features of the Company’s silicon nitride material are not well known, and the Company believes that the publication of such data would help sales efforts as the Company approaches new prospects. The Company is also making additional changes to the sales strategy, including a focus on revenue growth of silicon nitride lateral lumbar implants, the recently developed pedicle screw system known as Taurus, a variation of the Taurus system known as Taurus MIS and a newly developed interbody device known as C+CSC with Lumen. The Company has common stock that is publicly traded and has been able to successfully raise capital when needed since the date of the Company’s initial public offering. The Company has engaged in discussions with investment and banking firms to examine financing alternatives, including options to encourage the exercise of outstanding warrants and other lending alternatives. To this effect, in March 2018, the Company closed on gross proceeds of $1.4 million, before payment of placement agent fees and costs on a warrant reprice and exercise transaction. See discussion regarding Warrant Reprice March 2018 in Note 8 below. Additionally, on May 14, 2018, we closed on a public offering of units, consisting of convertible preferred stock and warrants, for gross proceeds of $15.0 million, which excludes underwriting discounts and commissions and offering expenses payable by the Company. These uncertainties create substantial doubt about our ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.
Reverse Stock Split	Reverse Stock Split On November 10, 2017, the Company effected a 1 for 12 reverse stock split of the Company’s common stock. The par value and the authorized shares of the common and convertible preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these condensed consolidated financial statements have been adjusted retroactively to reflect the reverse stock split.
Significant Accounting Policies	Significant Accounting Policies There have been no significant changes to the Company’s significant accounting policies as described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.
New Accounting Pronouncements Not Yet Adopted	New Accounting Pronouncements Not Yet Adopted In January 2017, the Financial Accounting Standards Board (“FASB”) issued ASU 2017-04 Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment In August 2016, the FASB updated accounting guidance on the following eight specific cash flow classification issues: (1) debt prepayment or debt extinguishment costs; (2) settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; (3) contingent consideration payments made after a business combination; (4) proceeds from the settlement of insurance claims; (5) proceeds from the settlement of corporate-owned life insurance policies, including bank-owned life insurance policies; (6) distributions received from equity method investees; (7) beneficial interests in securitization transactions; and (8) separately identifiable cash flows and application of the predominance principle. Under existing U.S. GAAP, there is no specific guidance on the eight cash flow classification issues aforementioned. These updates are effective for the Company for its annual period beginning January 1, 2019, and interim periods therein, with early adoption permitted. The guidance in this standard is not expected to have a material impact on the financial statements of the Company. In February 2016, the FASB updated the accounting guidance related to leases as part of a joint project with the International Accounting Standards Board (“IASB”) to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Under the new guidance, a lessee will be required to recognize assets and liabilities for capital and operating leases with lease terms of more than 12 months. Additionally, this update will require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases, including qualitative and quantitative requirements. The standard is effective for the Company for its annual period beginning January 1, 2020, and interim periods therein, with early adoption permitted. The Company is currently evaluating the potential impact this new standard may have on its financial statements but believes the most significant change will relate to building leases. In May 2014, in addition to several amendments issued during 2016, the FASB updated the accounting guidance related to revenue from contracts with customers, which supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle is that a company should recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The standard defines a five-step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP. The standard is effective for the Company for its annual period beginning January 1, 2019, and interim periods therein, and shall be applied either retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. The Company is in the preliminary stages of evaluating the impact that the new standard will have on its financial statements. The Company has reviewed all other recently issued, but not yet adopted, accounting standards, in order to determine their effects, if any, on its results of operations, financial position or cash flows. Based on that review, the Company believes that no other pronouncements will have a significant effect on its financial statements.
New Accounting Pronouncements Adopted During the Six Months Ended June 30, 2018	New Accounting Pronouncements Adopted During the Six Months Ended June 30, 2018 In March 2016, the FASB updated the accounting guidance related to stock compensation. This update simplifies the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as the well as classification in the statement of cash flows. The standard is effective for the Company for its annual period beginning January 1, 2018. The guidance in this standard did not have a material impact on the financial statements of the Company. The Company early adopted ASU 2017-11 - Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception.

Inventories, Net (Tables)

Inventories, Net (Tables)	6 Months Ended
	Jun. 30, 2018
Inventory Disclosure [Abstract]
Schedule of Components of Inventory	Inventories consisted of the following (in thousands): June 30, 2018 December 31, 2017 Raw materials $ 667 $ 740 WIP 75 52 Finished goods 1,718 1,585 $ 2,460 $ 2,377

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Intangible assets consisted of the following (in thousands): June 30, 2018 December 31, 2017 Developed technology $ 4,685 $ 4,685 Customer relationships 3,990 3,990 Other patents and patent applications 562 562 Trademarks 400 350 9,637 9,587 Less: accumulated amortization (7,205 ) (6,936 ) $ 2,432 $ 2,651

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2018
Schedule of Financial Liabilities Measured at Fair Value On Recurring Basis by Level Within Fair Value Hierarchy	The following tables set forth the financial liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of June 30, 2018 and December 31, 2017: Fair Value Measurements as of June 30, 2018 Description Level 1 Level 2 Level 3 Total Derivative liability Common stock warrants $ - $ - $ 6,561 $ 6,561 Fair Value Measurements as of December 31, 2017 Description Level 1 Level 2 Level 3 Total Derivative liability Common stock warrants $ - $ - $ 1,357 $ 1,357
Schedule of Fair Value Measurement Hierarchy of Derivative Liability	The Company did not have any transfers of assets and liabilities between Level 1 and Level 2 of the fair value measurement hierarchy during the six months ended June 30, 2018 and 2017. Common Stock Warrants Balance as of December 31, 2016 $ (3,665 ) Issuances of warrants classified as derivatives (810 ) Change in fair value 2,182 Balance as of June 30, 2017 $ (2,293 ) Balance as of December 31, 2017 $ (1,357 ) Issuances of warrants classified as derivatives (7,577 ) Change in fair value 2,020 Exercise of warrants 565 Other, net (212 ) Balance as of June 30, 2018 $ (6,561 )
Black-Scholes-Merton Valuation Model [Member]
Schedule of Assumptions Used in Estimating Fair Value	The assumptions used in estimating the common stock warrant liability using the Black-Scholes-Merton valuation model as of June 30, 2018 and December 31, 2017 were as follows: June 30, 2018 December 31, 2017 Weighted-average risk-free interest rate 2.73 % 1.89 % Weighted-average expected life (in years) 4.8 1.9 Expected dividend yield - % - % Weighted-average expected volatility 66 % 107 %
Monte Carlo Simulation Valuation Model [Member]
Schedule of Assumptions Used in Estimating Fair Value	The assumptions used in estimating the common stock warrant liability using the Monte Carlo Simulation valuation model as of June 30, 2018 and December 31, 2017 were as follows: June 30, 2018 December 31, 2017 Weighted-average risk-free interest rate 2.73 % 2.2 % Weighted-average expected life (in years) 3.7 3.6 Expected dividend yield - % - % Weighted average expected volatility 68 % 64 %

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2018
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consisted of the following (in thousands): June 30, 2018 December 31, 2017 Payroll and related expense $ 589 $ 311 Commissions 233 477 Royalties 76 96 Interest payable - 6 Final loan payment fees - 1,650 Other 69 142 $ 967 $ 2,682

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
Schedule of Outstanding Long-Term Debt	Long-term debt consisted of the following (in thousands): June 30, 2018 December 31, 2017 Outstanding Principal Unamortized Discount and Debt Issuance Costs Net Carrying Amount Outstanding Principal Unamortized Discount and Debt Issuance Costs Net Carrying Amount Hercules Term Loan $ - $ - $ - $ 605 $ - $ 605 North Stadium Loan 2,500 (21 ) 2,479 2,500 (144 ) 2,356 Total debt 2,500 (21 ) 2,479 3,105 (144 ) 2,961 Less: Current portion (2,500 ) 21 (2,479 ) (3,105 ) 144 (2,961 ) Long-term debt $ - $ - $ - $ - $ - $ -

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Stock Option Activity	A summary of the Company’s outstanding stock option activity for the six months ended June 30, 2018 is as follows: Options Weighted- Exercise Price Weighted- Average Intrinsic Value As of December 31, 2017 11,302 $ 264.26 7.3 $ - Granted - - - - Exercised - - - - Forfeited - - - - Expired - - - - As of June 30, 2018 11,302 $ 264.26 6.8 $ - Exercisable as of June 30, 2018 10,161 $ 272.59 7.7 $ - Expected to vest as of June 30, 2018 11,302 $ 264.26 6.8 $ -
Summary of Stock-Based Compensation Expense	Total stock-based compensation expense included in the condensed consolidated statements of operations is allocated as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Cost of revenue $ - $ 5 $ - $ 10 Research and development - 24 - 50 General and administrative 6 23 19 46 Selling and marketing 4 7 15 13 Capitalized into inventory - - - - $ 10 $ 59 $ 34 $ 119
Schedule of Unrecognized Stock-Based Compensation	Unrecognized stock-based compensation as of June 30, 2018 is as follows (in thousands): Unrecognized Stock-Based Compensation Weighted (in years) Stock options $ 3 -

Organization and Summary of S24

Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($) $ in Thousands	May 14, 2018	Nov. 10, 2017	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Accounting Policies [Abstract]
Net loss			$ 2,312		$ 1,703	$ 5,710	$ 2,215
Net cash used in operating activities						5,934	$ 3,430
Accumulated deficit			$ 226,340			$ 226,340		$ 220,629
Proceeds from issuance of private placement				$ 1,400
Proceeds from issuance of public offering	$ 15,000
Reverse stock split		1 for 12 reverse stock spli

Basic and Diluted Net Loss Pe25

Basic and Diluted Net Loss Per Common Share (Details Narrative) - shares	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Earnings Per Share [Abstract]
Dilutive securities	21,200,000	1,500,000

Inventories, Net (Details Narra

Inventories, Net (Details Narrative) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Finished goods included consigned inventory	$ 1,700	$ 500
Inventories, current	1,237	1,241
Inventories, non - current	$ 1,223	$ 1,136

Inventories, Net - Schedule of

Inventories, Net - Schedule of Components of Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 667	$ 740
WIP	75	52
Finished Goods	1,718	1,585
Total inventory	$ 2,460	$ 2,377

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) $ in Thousands	Jun. 30, 2018USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Estimated amortization expense for the remainder of 2018	$ 260
Estimated amortization expense, through 2021	536
Estimated amortization expense, 2022	369
Thereafter	$ 140

Intangible Assets - Schedule of

Intangible Assets - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Total intangibles	$ 9,637	$ 9,587
Less accumulated amortization	(7,205)	(6,936)
Total intangibles net of amortization	2,432	2,651
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Total intangibles	400	350
Developed Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Total intangibles	4,685	4,685
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Total intangibles	3,990	3,990
Other Patents And Patent Applications [Member]
Finite-Lived Intangible Assets [Line Items]
Total intangibles	$ 562	$ 562

Fair Value Measurements (Detail

Fair Value Measurements (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Financial assets measured on recurring basis
Weighted average price stock exceeds	$ 3
Average daily trading value	$ 350
Warrants [Member]
Weighted average price stock exceeds	$ 0.01
Black-Scholes-Merton Valuation Model [Member]
Derivative liability	$ 500	500
Monte Carlo Simulation Valuation Model [Member]
Derivative liability	$ 6,100	$ 900

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis by Level within Fair Value Hierarchy (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	$ 500	$ 461
Fair Value, Measurements, Recurring [Member] | Common Stock Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	6,561	1,357
Fair Value, Inputs, Level 1 [Member] | Fair Value, Measurements, Recurring [Member] | Common Stock Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability
Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member] | Common Stock Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability
Fair Value, Inputs, Level 3 [Member] | Fair Value, Measurements, Recurring [Member] | Common Stock Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	$ 6,561	$ 1,357

Fair Value Measurements - Sch32

Fair Value Measurements - Schedule of Fair Value Measurement Hierarchy of Derivative Liability (Details) - Common Stock Warrants [Member] - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Beginning balance	$ (1,357)	$ (3,665)
Issuances of warrants classified as derivatives	(7,577)	(810)
Change in fair value	2,020	2,182
Exercise of warrants	565
Other, net	(212)
Ending balance	$ (6,561)	$ (2,293)

Fair Value Measurements - Sch33

Fair Value Measurements - Schedule of Assumptions used in Estimating Fair Value (Details) - Common Stock Warrants [Member]	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Black-Scholes-Merton Valuation Model [Member] | Weighted-Average Risk-Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentages	2.73%	1.89%
Black-Scholes-Merton Valuation Model [Member] | Weighted-Average Expected Life [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, term	4 years 9 months 18 days	1 year 10 months 25 days
Black-Scholes-Merton Valuation Model [Member] | Expected Dividend Yield [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentages	0.00%	0.00%
Black-Scholes-Merton Valuation Model [Member] | Weighted-Average Expected Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentages	66.00%	107.00%
Monte Carlo Simulation Valuation Model [Member] | Weighted-Average Risk-Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentages	2.73%	2.20%
Monte Carlo Simulation Valuation Model [Member] | Weighted-Average Expected Life [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, term	3 years 8 months 12 days	3 years 7 months 6 days
Monte Carlo Simulation Valuation Model [Member] | Expected Dividend Yield [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentages	0.00%	0.00%
Monte Carlo Simulation Valuation Model [Member] | Weighted-Average Expected Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentages	68.00%	64.00%

Accrued Liabilities - Schedule

Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Payables and Accruals [Abstract]
Payroll and related expense	$ 589	$ 311
Commissions	233	477
Royalties	76	96
Interest payable		6
Final loan payment fees		1,650
Other	69	142
Total accrued liabilities	$ 967	$ 2,682

Debt (Details Narrative)

Debt (Details Narrative)	May 14, 2018USD ($)$ / shares	Jan. 03, 2018USD ($)$ / shares	Jul. 28, 2017USD ($)$ / sharesshares	Jun. 30, 2014USD ($)	Jan. 31, 2018USD ($)Integer$ / sharesshares	Jun. 30, 2018USD ($)	Jun. 30, 2017USD ($)	Dec. 31, 2017USD ($)	Jan. 31, 2017$ / shares	Apr. 04, 2016USD ($)
Debt principal amount						$ 2,500,000		$ 605,000
Warrant exercise price per share | $ / shares									$ 6.60
Total payoff amount						2,282,000	$ 3,324,000
Debt instrument conversion price | $ / shares	$ 1.45
North Stadium Investments, LLC [Member]
Debt principal amount			$ 2,500,000
Warrant to purchase shares of common stock | shares			55,000
Warrant exercise price per share | $ / shares			$ 5.04
Percentage of loan bear interest rate			10.00%
Debt maturity date			Jul. 28, 2018
Warrant term			5 years
Fair value of warrants			$ 200,000
Hercules Technology Capital, Inc. [Member] | Loan and Security Agreement [Member]
Debt principal amount				$ 20,000,000
Debt maturity date				Jan. 1, 2018
L2 Capital Debt [Member]
Debt principal amount	$ 700,000				$ 840,000
Debt purchase price					$ 750,000
Warrant to purchase shares of common stock | shares					68,257
Warrant exercise price per share | $ / shares					$ 3.31
Percentage of loan bear interest rate					8.00%
Percentage of default interest rate					18.00%
Debt trading per share | $ / shares					$ 0.70
Debt instrument trading days | Integer					20
Debt instrument, description					(i) 0.70 multiplied by (ii) the lowest volume weighted average price, or VWAP, of the Company's common stock during the 20-day trading period ending in the holder of the L2 note's sole discretion on the last complete trading day prior to conversion, or, the conversion date.
Gross proceeds of convertible preferred stock and warrants	15,000,000
Total payoff amount	1,100,000
Interest amount	400,000
Hercules Term Loan [Member]
Debt principal amount		$ 2,264,623						$ 605,000
Hercules Term Loan [Member] | Closing Date [Member]
Term loan fee amount						200,000
Final payment fee for debt						$ 1,700,000
Hercules Term Loan [Member] | Riverside Merchant Partners, LLC [Member]
Debt additional principal										$ 2,000,000
Hercules Term Loan [Member] | Senior Secured Convertible Promissory Notes One [Member]
Debt principal amount		1,100,000
Hercules Term Loan [Member] | Senior Secured Convertible Promissory Notes Two [Member]
Debt principal amount		$ 2,200,000
Exchange Notes [Member]
Percentage of loan bear interest rate		15.00%
Debt trading per share | $ / shares		$ 1.75
Debt instrument, description		(i) in no event may the Alternate Conversion Price be less than $1.75 per share and (ii) the Assignees shall not be entitled to receive more than 19.99% of the outstanding common stock. So long as these Exchange Notes remain outstanding or the Assignees hold any Conversion Shares, the Company is prohibited from entering into any financing transaction pursuant to which the Company sells its securities at a price lower than $1.75 per share.
Debt maturity date		Feb. 3, 2019
Debt instrument conversion price | $ / shares		$ 3.87
Debt instrument trading percentage		70.00%
MEF I, L.P. and Anson Investments [Member]
Debt principal amount	1,400,000
Gross proceeds of convertible preferred stock and warrants	15,000,000
Total payoff amount	1,600,000
Interest amount	$ 200,000
North Stadium Investments, LLC [Member] | July 2018 [Member]
Debt instrument, description						Due date of the loan from July 28, 2018 to XXX, 2018,
Riverside Merchant Partners, LLC [Member]
Debt principal amount						$ 3,000,000
Subordinated convertible promissory notes						3,000,000
Riverside Merchant Partners, LLC [Member] | Hercules and Riverside Debt Assignment [Member]
Debt principal amount										1,000,000
Debt additional principal										$ 2,000,000
Riverside Merchant Partners, LLC [Member] | Hercules Term Loan [Member]
Debt principal amount						$ 3,000,000

Debt - Schedule of Outstanding

Debt - Schedule of Outstanding Long-Term Debt (Details) - USD ($)	Jun. 30, 2018	Jan. 03, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Total debt, Outstanding Principle	$ 2,500,000		$ 605,000
Total debt, Unamortized Discount and Debt Issuance Costs	(21,000)		2,356,000
Total debt, Net Carrying Amount	2,479,000		2,961,000
Current portion, Outstanding Principle	(2,500,000)		3,105,000
Current portion, Unamortized Discount and Debt Issuance Costs	21,000		(144,000)
Current portion, Net Carrying Amount			(605,000)
Long-term debt, Outstanding Principle
Long-term debt, Unamortized Discount and Debt Issuance Costs
Long-term debt, Net Carrying Amount
Hercules Term Loan [Member]
Debt Instrument [Line Items]
Total debt, Outstanding Principle		$ 2,264,623	605,000
Total debt, Unamortized Discount and Debt Issuance Costs			2,500,000
Total debt, Net Carrying Amount			3,105,000
North Stadium Loan [Member]
Debt Instrument [Line Items]
Total debt, Outstanding Principle	2,500,000
Total debt, Unamortized Discount and Debt Issuance Costs	(21,000)		(144,000)
Total debt, Net Carrying Amount	$ 2,479,000		$ (144,000)

Equity (Details Narrative)

Equity (Details Narrative) $ / shares in Units, $ in Thousands	May 14, 2018USD ($)Integer$ / sharesshares	May 31, 2018USD ($)shares	Jan. 31, 2017USD ($)$ / sharesshares	Jul. 31, 2016USD ($)$ / sharesshares	Jun. 30, 2018USD ($)$ / sharesshares	Jun. 30, 2017USD ($)	Mar. 31, 2018shares	Dec. 31, 2017$ / sharesshares
Warrants to purchase of common stock shares | shares		145,834					832,000
Gross proceeds of warrants		$ 300,000			$ 7,577	$ 679
Proceeds from public offering	$ 15,000
Preferred stock stated value | $ / shares					$ 0.01			$ 0.01
Common stock state value | $ / shares					0.01			$ 0.01
Conversion price per share | $ / shares	$ 1.45
Share price | $ / shares					$ 3
Warrants exercise price | $ / shares			$ 6.60
Proceeds from issuance of units	$ 15,000				$ 6,754
Preferred stock issuance costs	6,800
Allocated to preferred stock	$ 600
Warrants issuance cost			$ 100,000
Allocated to warrants			800,000
Proceeds from warrant exercised					1,633
Proceeds from issuance of common stock gross			3,900,000
Proceeds from issuance of common stock net			3,100,000			3,128
Stock issuance cost			$ 600,000
Warrants expire term			5 years
Common stock, issued | shares					7,509,248			3,028,065
Preferred stock, issued | shares					10,928			10,928
Investors [Member]
Warrants to purchase of common stock shares | shares					832,000
Warrants exercise price | $ / shares					$ 12
Investors [Member] | Amendment Agreement [Member]
Warrants to purchase of common stock shares | shares					668,335
Warrants exercise price | $ / shares					$ 2.125
Proceeds from warrant exercised					$ 1,400,000
July 12, 2018 [Member]
Conversion price per share | $ / shares					$ 0.6543
Public Offering [Member]
Stock issued price per shares | $ / shares	$ 1,000
Debt instrument trading days | Integer	40
Conversion price per share | $ / shares	$ 1.4512
Debt instrument trading percentage	87.50%
Share price | $ / shares	$ 0.48
Units price per unit | $ / shares	$ 1,000
Secondary Offering [Member]
Gross proceeds of warrants				$ 11,400,000
Convertible Preferred Stock and Warrants [Member]
Proceeds from public offering	$ 15,000
Warrants [Member]
Warrants to purchase of common stock shares | shares	758
Warrant term	5 years
Common stock state value | $ / shares	$ 1,100
Share price | $ / shares					0.01
Warrants exercise price | $ / shares	$ 1.60
Warrants issuance cost	$ 6,900
Allocated to warrants	700
Warrants for derivative liability	$ 700
Warrants [Member] | Secondary Offering [Member]
Warrants to purchase of common stock shares | shares			363,750	1,054,167
Warrants exercise price | $ / shares				$ 12
New Warrants [Member]
Warrants exercise price | $ / shares					$ 2
Ownership percentage					100.00%
Common Stock [Member]
Stock issued price per shares | $ / shares					$ 6.48
Stock issuance cost					$ 682	$ 682
Units price per unit | $ / shares					$ 6.48
Common Stock [Member] | Secondary Offering [Member]
Number of shares of common stock sold | shares			741,667
Common stock, issued | shares				438,167
Preferred Stock [Member]
Convertible preferred stock shares conversion | shares					616,000
Stock issuance cost					$ 668
Preferred stock, issued | shares					7,392
Preferred Stock [Member] | Secondary Offering [Member]
Convertible preferred stock shares conversion | shares				616,000
Preferred stock, issued | shares				7,392
Series B Convertible Preferred Stock [Member]
Convertible preferred stock shares conversion | shares		4,072			4,072
Preferred stock stated value | $ / shares	$ 1,100
Common Stock [Member]
Convertible preferred stock shares conversion | shares	11,369,900	3,086,570			3,086,570
Preferred Stock [Member]
Convertible preferred stock shares conversion | shares	15,000
Class A Units [Member]
Allocated to warrants					$ 2,400,000
Proceeds from issuance of common stock gross					4,900,000
Proceeds from issuance of common stock net					2,500,000
Stock issuance cost					300,000
Class A Units [Member] | Secondary Offering [Member]
Convertible preferred stock shares conversion | shares				83
Warrants to purchase of common stock shares | shares				83
Stock issued price per shares | $ / shares				$ 1
Number of shares of common stock sold | shares				5,258,000
Units price per unit | $ / shares				$ 1
Class A Units [Member] | Secondary Offering [Member] | Underwriter [Member]
Number of shares of common stock sold | shares				1,650,000
Class B Units [Member]
Warrants issuance cost					500,000
Allocated to warrants					3,400,000
Warrants for derivative liability					5,800,000
Proceeds from issuance of common stock gross					7,000,000
Proceeds from issuance of common stock net					3,600,000
Stock issuance cost					$ 400,000
Class B Units [Member] | Secondary Offering [Member] | Underwriter [Member]
Stock issued price per shares | $ / shares				$ 1,000
Number of shares of common stock sold | shares				7,392
Units price per unit | $ / shares				$ 1,000
Convertible Preferred Stock [Member] | Secondary Offering [Member]
Convertible preferred stock shares conversion | shares					616,000
Preferred stock, issued | shares					7,392
Number of common stock received					$ 400,000
Number of common stock exercise, shares | shares					37,208

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity (Details)	6 Months Ended
	Jun. 30, 2018USD ($)$ / sharesshares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Options, Outstanding at beginning of period | shares	11,302
Options, Granted | shares
Options, Exercised | shares
Options, Forfeited | shares
Options, Expired | shares
Options, Outstanding at end of period | shares	11,302
Options, Exercisable at end of period | shares	10,161
Options, Vested and expected to vest at end of period | shares	11,302
Weighted Average Exercise Price, Outstanding at beginning of period | $ / shares	$ 264.26
Weighted Average Exercise Price, Granted | $ / shares
Weighted Average Exercise Price, Exercised | $ / shares
Weighted Average Exercise Price, Forfeited | $ / shares
Weighted Average Exercise Price, Expired | $ / shares
Weighted Average Exercise Price, Outstanding at end of period | $ / shares	264.26
Weighted Average Exercise Price, Exercisable at end of period | $ / shares	272.59
Weighted Average Exercise Price, Vested and expected to vest at end of period | $ / shares	$ 264.26
Weighted Average Remaining Contractual Terms (Years), Outstanding	7 years 3 months 19 days
Weighted Average Remaining Contractual Terms (Years), Outstanding	6 years 9 months 18 days
Weighted Average Remaining Contractual Terms (Years), Exercisable	7 years 8 months 12 days
Weighted Average Remaining Contractual Terms (years), Vested and expected to vest	6 years 9 months 18 days
Intrinsic Value, Outstanding at beginning of period | $
Intrinsic Value, Outstanding at end of period | $
Intrinsic Value, Exercisable at end of period | $
Intrinsic Value, Vested and expected to vest at end of period | $

Stock-Based Compensation - Su39

Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	$ 10	$ 59	$ 34	$ 119
Cost of Revenue [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense		5		10
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense		24		50
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	6	23	19	46
Selling and Marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	4	7	15	13
Capitalized into Inventory [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Unrecognized Stock-Based Compensation (Details) - Employee Stock Option [Member] $ in Thousands	6 Months Ended
	Jun. 30, 2018USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation	$ 3
Weighted average remaining period of recognition (in years)	0 years